Resources

Patient Resources (by PBC Ireland)

📝 Clinic Visit Questionnaire (pdf)
Complete the form in advance, bring it with you to your clinic visit, and hand it to your consultant.
Use it as a guide to make sure everything you’ve ticked is discussed before you leave.

New PBC Drugs Monitor

(last checked: 25/5/2025)
Elafibranor (Iqirvo®) : Available ❌ | HSE HT Approval ❌ | NCPE (HTA ID: 25005)⌛ | IQIRVO (Ipsen) | EMA Approval ✅ | ELATIVE® Trial
Seladelpar (Lyvdelzi®) : Available ❌ | HSE HT Approval ❌ | NCPE (HTA ID: N)❌ | Lyvdelzi® (Gilead) | EMA Approval ✅ | ASSURE Trial, RESPONSE Trial

Investigational Therapies (in the pipeline)

There are several new drugs in early to mid-stage development for PBC. Some focus on relieving pruritus by reducing bile acid levels through inhibition of bile acid transport (IBAT). Others aim to address both cholestasis and metabolic dysfunction by targeting nuclear receptors (PPARα/γ) involved in lipid and bile acid metabolism. Additional candidates are designed to reduce liver inflammation and fibrosis, offering potential benefits in slowing disease progression.
(last checked: 2/6/2025)
• Volixibat (Mirum Pharmaceuticals): An IBAT inhibitor in Phase IIb trials. Shows strong anti-pruritic effects and bile acid reduction.
• Linerixibat (GlaxoSmithKline): An IBAT inhibitor in Phase III trials, focusing on alleviating pruritus associated with PBC.
• Saroglitazar (Zydus Lifesciences): A dual PPARα/γ agonist in Phase IIb/III trials. It targets both cholestasis and metabolic dysfunction in PBC.
• Cilofexor (Gilead Sciences): FXR agonist, Phase: II, Showed significant reductions in ALP, GGT, and CRP in patients not responding to UDCA, with a tolerable side-effect profile.
• Setanaxib (Genkyotex/Ipsen): NOX1/4 inhibitor. Phase: IIb/III. Targets liver fibrosis and inflammation, with early signs of efficacy in reducing fatigue and improving biochemical markers.

Tips for living with PBC

Primary Biliary Cholangitis (Irish Liver Foundation)
Living with primary biliary cholangitis (British Liver Trust)
Primary biliary cholangitis (PBC) - Living with your diagnosis (Canadian PBC Society)
Primary biliary cholangitis: Lifestyle do's and don'ts (Mayo Clinic)
Primary Biliary Cholangitis (PBC): Living With This Chronic Disease (Cleveland Clinic)

Diet and wellness tips

The PBC Diet: What to Eat, What to Avoid (American Liver Foudation)
Using Food To Manage Primary Biliary Cholangitis (Cleveland Clinic)
Primary biliary cholangitis: Your guide to diet and nutrition (Mayo Clinic)
Health Eating (Canadian PBC Society)

Useful Websites (Irish)

Beaumont Hospital (Hepatology Dept.)
Irish Liver Foundation
Mater Hospital (Centre for Liver Disease)
St. James' (Hepatology Centre)
St. Vincent's (Hepatology Dept.)
Liver Ireland Support Network (LISN)

Useful Websites (International)

PBC Foundation (UK)
PBCers (USA)
American Liver Foundation (USA)
Canadian PBC Society (Canada)
Cleveland Clinic (USA)

PBC in the News (The latest 5 articles from Google News)

12/02/2026 GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® - GlobeNewswire

12/02/2026 Primary biliary cholangitis–associated osteoporosis: contemporary review of pathogenesis and management - EurekAlert!

11/02/2026 Shifting the Clinical Conversation Around Statins in PBC, With Jonggi Choi, MD, PhD - HCPLive

11/02/2026 Noninvasive combo tests for liver damage could replace biopsies in PBC - Liver Disease News

11/02/2026 Primary Biliary Cholangitis Market: Accelerating Growth and Pipeline Impact by 2034 - DelveInsight - openPR.com

See All PBC in the News

Guidelines

Primary biliary cholangitis (PBC) - Living with your diagnosis (Canadian PBC Society)
Diagnosis and Treatment of Primary Biliary Cholangitis: A Patient‐Friendly Summary of the 2018 AASLD Practice Guidance
PBC primary biliary cholangitis treatment and management guidelines (the British Society of Gastroenterology/UK)
EASL Clinical Practice Guidelines: The Diagnosis and management of patients with Primary Biliary Cholangitis (Lay terms)
EASL Clinical Practice Guidelines: The Diagnosis and management of patients with Primary Biliary Cholangitis (Journal of Hepatology)

Publications (The latest 5 articles from PubMed)

Chen S, et al. 2026. Direct bilirubin was superior to total bilirubin in predicting the long-term outcomes of patients with primary biliary cholangitis. BMC Gastroenterol (Feb 2026)

Xu J, et al. 2025. Elevated Serum Soluble Tim-3 in Primary Biliary Cholangitis: Lack of Correlation with Cytokines, Chemokines, and Clinical Parameters. Turk J Gastroenterol (Aug 2025)

Lou J, et al. 2026. Longitudinal multi-omics pilot study: Small sample size human model of gut microbiota-mitochondrial metabolic dysregulation in primary biliary cholangitis. Microbiol Res (Feb 2026)

Yang J, et al. 2026. Primary Biliary Cholangitis-associated Osteoporosis: Contemporary Review of Pathogenesis and Management. J Clin Transl Hepatol (Jan 2026)

Chen R, et al. 2026. A multifaceted analysis of OTUD5 integrated MAVS in innate immunity of Primary Biliary Cholangitis. PLoS One (2026)

See 100 Publications

Media

Press Contact: Gerry Nesbitt, gerry@PBCireland.org

Logo: 1024x1024.png 3064x3064.png Logo Black